<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="94033">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01837355</url>
  </required_header>
  <id_info>
    <org_study_id>EKSG 12/129/1B</org_study_id>
    <nct_id>NCT01837355</nct_id>
  </id_info>
  <brief_title>Modulation of Intestinal and Pulmonary Inflammation by Lactobacillus Diet Supplementation in Pediatric Cystic Fibrosis</brief_title>
  <acronym>MoHuM-1</acronym>
  <official_title>Modulation of Intestinal and Pulmonary Inflammation by Lactobacillus Rhamnosus Diet Supplementation in Pediatric Cystic Fibrosis (MoHuM-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cantonal Hospital of St. Gallen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss Federal Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cantonal Hospital of St. Gallen</source>
  <oversight_info>
    <authority>Switzerland: Swissmedic</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary inflammation is an independent risk factor for disease progression in cystic
      fibrosis patients (CF). Yet, no effective treatment is known to reduce this detrimental
      inflammation. Dysbiosis of the gut microbiota has been linked to inflammation in several
      inflammatory diseases. As children with CF have different faecal microbiota from their
      healthy siblings, modulating gut microbiota by lactobacillus rhamnosus diet supplementation
      might be a strategy to target the inflammatory state in CF. Study subjects (CF or healthy
      control) will receive either placebo or lactobacillus rhamnosus once daily as dietary
      supplementation for 12 weeks. After a one-week washout phase, they will be switched for
      another 12 weeks to the other trial arm. Effect on in intestinal and pulmonary inflammation
      as well as clinical outcome will be studied.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline at w12 and w24 in fecal calprotectin levels</measure>
    <time_frame>Baseline, week 12, week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Baseline, week 12 change from baseline, week 24 change from week 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline at w12 and w24 in pulmonary calprotectin levels</measure>
    <time_frame>Baseline, w12, w24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Baseline, week 12 change from baseline, week 24 change from week 12</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Pulmonary Inflammation</condition>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactobacillus rhamnosus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lactobacillus rhamnosus once daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus rhamnosus</intervention_name>
    <arm_group_label>Lactobacillus rhamnosus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  moderate to severe CF disease

        Exclusion Criteria:

          -  acute gastroenteritis 2 weeks prior to inclusion

          -  chronic disease other than CF (except CF associated disorders)

          -  oral or parenteral antibiotics 2 weeks prior to inclusion

          -  systemic steroids 4 weeks prior to inclusion

          -  any probiotic intake
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christian Kahlert, MD</last_name>
    <phone>+41714941111</phone>
    <email>christian.kahlert@kssg.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pascal Müller, MD</last_name>
    <phone>+4142437111</phone>
    <email>pascal.mueller@kispisg.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Childrens's Hospital of Eastern Switzerland</name>
      <address>
        <city>St. Gallen</city>
        <state>SG</state>
        <zip>9008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Müller, MD</last_name>
      <phone>+41712437111</phone>
      <email>pascal.mueller@kispisg.ch</email>
    </contact>
    <contact_backup>
      <last_name>Christian Kahlert, MD</last_name>
      <phone>+41714941111</phone>
      <email>christian.kahlert@kssg.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Pascal Müller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 22, 2013</lastchanged_date>
  <firstreceived_date>April 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cantonal Hospital of St. Gallen</investigator_affiliation>
    <investigator_full_name>Christian R Kahlert, MD</investigator_full_name>
    <investigator_title>Consultant Pediatric Infectious Diseases</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
